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Abstract
Activating epidermal growth factor receptor (EGFR) mutations are recognized biomarkers for patients with metastatic non-
small cell lung cancer (NSCLC) treated with EGFR tyrosine kinase inhibitors (TKIs). EGFR TKIs can also have activity against
NSCLC without EGFR mutations, requiring the identification of additional relevant biomarkers. Previous studies on tumor
EGFR protein levels and EGFR gene copy number revealed inconsistent results. The aim of the study was to identify novel
biomarkers of the response to TKIs in NSCLC by investigating whole genome expression at the exon-level. We used exon
arrays and clinical samples from a previous trial (SAKK19/05) to investigate the expression variations at the exon-level of 3
genes potentially playing a key role in modulating treatment response: EGFR, V-Ki-ras2 Kirsten rat sarcoma viral oncogene
homolog (KRAS) and vascular endothelial growth factor (VEGFA). We identified the expression of EGFR exon 18 as a new
predictive marker for patients with untreated metastatic NSCLC treated with bevacizumab and erlotinib in the first line
setting. The overexpression of EGFR exon 18 in tumor was significantly associated with tumor shrinkage, independently of
EGFR mutation status. A similar significant association could be found in blood samples. In conclusion, exonic EGFR
expression particularly in exon 18 was found to be a relevant predictive biomarker for response to bevacizumab and
erlotinib. Based on these results, we propose a new model of EGFR testing in tumor and blood.
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Introduction
The prognosis of patients with stage IV non-small cell lung
cancer (NSCLC) continues to be poor. Despite standard cytotoxic
chemotherapy, almost 50% will not survive more than 12–14
months [1,2]. In the past few years, improvements in survival rates
have primarily been achieved by the discovery of predictive
molecular markers which identified subgroups of patients deriving
a substantial benefit from targeted treatment. Several randomized
phase III trials have recently shown a significant benefit of
epidermal growth factor receptor tyrosine kinase inhibitors
(EGFR-TKIs) in chemotherapy naı¨ve patients harboring an
activating EGFR mutation [3–6]. EGFR mutations are found in
about 10–15% of Caucasian patients [7]. In EGFR wild-type
patients the first-line treatment with an EGFR-TKI might even
harm compared to conventional chemotherapy [8]. However, in
unselected chemotherapy-naı¨ve patients the role of EGFR-TKIs is
less clear and previous studies have demonstrated inferior
outcomes with TKIs with or without bevacizumab compared to
chemotherapy [9–11]. These results indicate, that there is a
subgroup of EGFR wild-type patients who might benefit from
treatment with a TKI or a TKI plus an anti-angiogenic agent. The
same holds true for unselected and pretreated patients where the
role of TKIs has been addressed in numerous trials and the
efficacy and survival rates have shown to be comparable to
conventional chemotherapy [12–14]. Furthermore, recent bio-
marker analyses of three large trials testing maintenance therapy
with erlotinib clearly demonstrated, that a subset of EGFR wild-
type patients also derive a significant benefit from EGFR-TKI
therapy [15–17].
Beside EGFR other druggable oncogenic mutations in ad-
vanced NSCLC have been described [18,19]. Unfortunately, most
patients with NSCLC do not harbor a corresponding molecular
target hence chemotherapy continues to be their first treatment of
choice. Therefore, the identification of further subgroups of







































patients who may derive benefit from targeted treatment by
exploring additional molecular markers is crucial.
Treatment with bevacizumab and erlotinib (BE) has potential
benefits over chemotherapy, particularly in regard to its more
favorable toxicity profile. There is evidence, that the addition of
the vascular endothelial growth factor (VEGF) targeting mono-
clonal antibody bevacizumab to the EGFR-TKI erlotinib exhibits
increased efficacy compared with erlotinib alone in unselected
patients who were previously treated with chemotherapy [20].
This observation likely results from enhanced erlotinib activity,
given the lack of efficacy of bevacizumab monotherapy in lung
cancer.
The Swiss Group for Clinical Cancer Research (SAKK)
recently reported a median time to progression (TTP) of 4.1
months in patients with untreated advanced non-squamous
NSCLC treated with BE [21]. This result appears to be inferior
to what would be expected with modern chemotherapy combi-
nations in similar patient populations [2,22]. In the current
substudy, we aimed to identify a potential subgroup of patients
participating in the SAKK 19/05 trial, particularly within the
EGFR wild-type group, who may benefit from treatment with BE.
The main goal of this study was to assess the correlation of exon-
level expression variations of 3 specific genes [EGFR, V-Ki-ras2
Kirsten rat sarcoma viral oncogene homolog (KRAS) and vascular
endothelial growth factor A (VEGFA)] and the response to first
line BE therapy in patients who participated in the SAKK 19/05
trial.
Results
Patient characteristics and clinical outcome
The SAKK 19/05 trial included 103 patients, 101 were
evaluable for the primary statistical analysis. Overall, median
age was 65 (range, 32–80) years. All patients were in a good
performance status (WHO 0-1), 48 were male (48%), 53 were
female (52%). The majority (86%) had stage IV disease. EGFR
mutations were identified in 15 patients (15%). One patient had a
primary resistance mutation T790M in exon 20. KRAS mutation
were identified in 13 patients (13%). Objective tumor responses at
12 weeks (PR or CR) were observed in 15 patients (15%). These
patients had the following EGFR mutational status: EGFR del19
(n = 5), L858R (n = 2), unknown mutational status (n = 1), and
EGFR wild-type (n = 8). One patient with EGFR wild-type and
response to BE therapy had a KRAS mutation G12D.
From these patients, tumor tissue for exon array analysis was
obtained from 42 patients and blood samples from 75 patients
(Table S1 in the Supporting Information). A detailed description
of patient characteristics is provided in Table 1 (tumor tissue
samples) and in Table 2 (blood samples). Tissue samples
corresponded to our primary dataset used for biomarker
identification. Blood samples were used for confirmatory purpose
(validation set).
Target gene expression analysis on exon-level
Epidermal growth factor-receptor (EGFR). EGFR gene
expression was measured at 451 loci, of which 51 were situated
within exons, and 400 were situated outside of exons, i.e. intronic,
intergenic or were unreliable (Figure 1, upper panel). Thus, a total
of 51 exon probesets expression intensities were measured within
the EGFR gene. A summary measure of all these exon-level
probesets was provided by PCA (scores on the first PC axis). The
association between this score and TS12 and TTP under BE, OS,
and TTP under chemotherapy was evaluated.
We found a significant correlation between EGFR PCA scores
and TS12 after BE treatment (Spearman’s r~0:502, p~0:006)
(Figure 2A, left panel). A detailed analysis probeset-by-probeset
revealed that 86% of the exonic probesets showed a significant
correlation with tumor shrinkage without correction for multiple
testing (pv0:05) (Figure 2B, left panel). Two probesets showed a
particularly strong correlation with TS12 (exon probesets ID
3002770 and 3002769), which remained significant after Bonfer-
roni correction for multiple testing. These 2 probesets are located
on exon 18 (chromosome 7, positions 55’238’440 and 55’238’092,
respectively). No other significant associations were found. Six
patients had TTP of 15 months or more. Three of those had
EGFR del19, and 3 were EGFR and KRAS wild-type.
Figure 3 depicts the significant association of exon 18-EGFR
expression intensity and TS12. The left panel shows a strong
association between the expression intensity of exon 18-EGFR
(probeset 3002770) and TS12 (Spearman’s r~0:69, pv0:0001).
The strong correlation between EGFR exon 18 expression and
TS12 remained highly significant (Spearman’s r~0:61,
p~0:0015) after restricting the analysis to EGFR wild type
patients (see Figure S1 in the supporting information). This sub-
analysis indicates that the association between EGFR exon 18
expression and TS12 was independent from the EGFR mutation
status.
The ROC analysis (middle panel) shows the relationship
between sensitivity and specificity depending on different cut-off
levels of exon 18-EGFR (probeset 3002770) expression to classify
patients into ‘‘responders’’ vs. ‘‘non-responders’’. For the purpose
of this ROC analysis, the categorization ‘‘responders’’ vs. ‘‘non-
responders’’ derived from TS12. We proposed 3 alternative
definitions to ‘‘responders’’ by setting the TS12 cut-off as greater
or equals to 0, 20, or 30%, depending on whether or not one
included all or a fraction of stable disease patients in the
‘‘responders’’ category. Using the median expression of EGFR
probeset 3002770 as test-threshold provides a classification
accuracy of 75% (sensitivity = 100%, specificity = 67%). As shown
in the ROC curve, a higher classification accuracy can be
expected by further fine tuning this threshold (area under curve
[AUC] = 0.93).
The 2 exon 18-EGFR probesets showing the strongest
correlation with TS12 also showed a significant association for
the same endpoint when measured using blood (pv0:05).
The stability of our finding was assessed using bootstrapping,
and cross-validation strategies. The procedure confirmed the
strong classification accuracy of exon 18 EGFR with a median
ROC-AUC of 0.94 (95% CI: 0.70–1.00) and the specific
association between the exon 18 region and tumor shrinkage at
week 12 (see Figure S2 and Text S1 for detailed procedure).
Kirsten rat sarcoma viral oncogene homolog (KRAS) and
vascular endothelial growth factor-alpha (VEGFA). In total,
13 and 25 exon probesets expression intensities were measured
within KRAS and VEGFA respectively (Figure 1, central and right
panels). The PCA scores obtained for both sets of probeset (KRAS
and VEGFA) did not show significant association with any of the
clinical endpoints. A detailed analysis probeset-by-probeset did not
reveal any significant association with either TS12 (Figure 2A, B,
central and right panels) or the other investigated endpoints.
Discussion
To our knowledge, this is the first study exploring the
correlation between gene expression assessed at a subgenic exonic
level using Affymetrix Human Exon 1.0 ST arrays and response to
treatment with an EGFR-TKI in combination with an anti-
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angiogenic agent. We investigated the exon intensity variations
within 3 key genes (EGFR, KRAS and VEGFA) potentially
associated with response to treatment with BE. We were able to
demonstrate a strong association between the majority, but not all,
of the 51 EGFR exon probesets and TS12 of first-line BE therapy
in patients with untreated advanced non-squamous NSCLC. Exon
18-EGFR levels showed the best association with response to BE.
Based on our previous experiments we assume that the signal we
Table 1. Patients’ details for patients with treatment naive biopsies.
UPN Age Gender Stage Smoking status DST W12 EGFR mut (18–21) KRAS mut (12)
Tumor shrinkage
W12 (%)
2 69 M IV smoker 0 NA NA 65
23 53 F IV smoker 0 no no 17
38 58 F IV never smoker 0 NA NA NA
49 56 M IV smoker 1 no no 215
51 70 F IIIB never smoker 0 no no 18
55 55 F IV smoker 0 no no NA
56 61 F IV never smoker 1 NA NA 23
57 66 F IV smoker 0 no no NA
58 46 F IV smoker 0 no G12D NA
60 64 F IV never smoker 1 no G12D 53
61 61 F IV never smoker 1 L858R no 36
63 48 F IIIB smoker 0 no no NA
64 64 M IV smoker 1 no no 21
65 67 F IV never smoker 0 no no NA
67 53 M IV smoker 1 no no 21
68 63 M IV smoker 0 no G12D NA
69 66 F IIIB smoker 0 no no 22
70 35 M IV smoker 1 no no 5
74 61 M IV never smoker 1 no no 66
75 61 M IV never smoker 0 no no NA
76 51 F IV smoker 1 no G12C 3
77 54 M IV smoker 1 no no 16
78 63 F IV smoker 1 Del L747-G749 NA 26
80 44 F IV smoker 0 NA NA NA
81 55 M IV smoker 0 no no NA
82 58 M IV smoker 1 no no 0
83 53 F IV smoker 0 no G12D NA
84 55 F IV never smoker 1 NA NA 0
87 74 M IV smoker 1 no no 215
88 78 M IV never smoker 0 no no 23
90 69 F IV smoker 1 no no 0
91 68 M IV smoker 0 no no NA
93 56 F IV never smoker 1 E709A and G719S no 12
94 49 F IV smoker 1 no G12V 16
95 64 M IV smoker 1 NA NA 1
96 77 M IV smoker 0 no no NA
97 68 F IV smoker 0 no no NA
98 64 F IV never smoker 1 no no 18
99 48 M IV smoker 1 no no 26
101 66 M IV smoker 0 no no 21
102 59 F IV smoker 1 no no 28
103 72 F IV never smoker 1 Del E746-A750 no 76
Abbreviations: DST W12: disease stabilization week 12, 0 = failure, 1 = success; EGFR mut (18–21): EGFR mutation in exons 18–21; KRAS mut (12): KRAS mutation in exon
12; W12: week 12.
doi:10.1371/journal.pone.0072966.t001
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Table 2. Patients’ details for patients in the blood study.






2 69 M IV smoker 0 NA NA 65
3 50 M IV smoker 1 no G12C 26
7 55 M IV smoker 0 no G12C 233
8 65 F IV smoker 0 no no NA
9 61 M IV smoker 0 no no 241
14 53 M IV smoker 0 no NA 15
15 55 F IV smoker 0 no NA NA
16 75 M IV never smoker 1 Del L747-E749 no 100
18 64 M IV never smoker 1 L858R no 45
19 62 M IV smoker 0 NA NA NA
20 74 M IV smoker 1 no no 6
21 59 F IV smoker 1 no no 43
23 53 F IV smoker 0 no no 17
25 59 M IV smoker 0 no no NA
26 58 M IV smoker 1 no no 11
27 72 M IV smoker 0 NA NA 222
28 68 F IV smoker 0 no no NA
29 57 M IIIB smoker 1 no no 13
30 65 F IIIB never smoker 0 no no NA
37 61 M IV smoker 0 no NA NA
38 58 F IV never smoker 0 NA NA NA
39 68 M IV smoker 0 R705GA G12A NA
40 53 M IV smoker 1 no no 5
42 51 F IV smoker 1 no no 23
44 51 F IV smoker 0 no G12C NA
47 72 M IV smoker 1 no no 25
49 56 M IV smoker 1 no no 215
50 63 M IV smoker 1 NA NA 12
51 70 F IIIB never smoker 0 no no 18
53 49 F IV smoker 1 NA NA 212
54 49 M IV smoker 1 Del L747-S751_InsS no 27
55 55 F IV smoker 0 no no NA
56 61 F IV never smoker 1 NA NA 23
57 66 F IV smoker 0 no no NA
58 46 F IV smoker 0 no G12D NA
59 47 F IV smoker 1 no no 27
60 64 F IV never smoker 1 no G12D 53
61 61 F IV never smoker 1 L858R no 36
63 48 F IIIB smoker 0 no no NA
64 64 M IV smoker 1 no no 21
65 67 F IV never smoker 0 no no NA
66 57 F IIIB never smoker 1 no no 12
67 53 M IV smoker 1 no no 21
68 63 M IV smoker 0 no G12D NA
69 66 F IIIB smoker 0 no no 22
70 35 M IV smoker 1 no no 5
72 56 F IIIB smoker 1 no G12D 215
73 54 M IV smoker 0 no NA NA
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measured in EGFR Exon 18 did not depend on the tumor cell
content [23]. Furthermore, there was a quantitative relationship -
higher EGFR mRNA level was correlated with more pronounced
tumor shrinkage, independently of EGFR mutational status.
EGFR exon-level expression analysis might become a useful
biomarker for daily clinical practice as it provides several
advantages in comparison to conventional mutational analysis by
gene sequencing. Typically, EGFR gene expression is measured
using quantitative RT-PCR with primers binding to a single gene
region often near the 39-end of the gene. However, as shown in
our study, gene expression did significantly vary over the span of
the EGFR gene. Reasons for such expression variations include
alternative splicing. The EGFR variant type III (EGFRvIII) has an
in-frame deletion of exons 2–7 which has been found to be
generated by gene rearrangement or aberrant mRNA splicing
[24,25]. This alternative splicing form has been found in NSCLC
[26,27]. In preclinical experiments, cells expressing EGFRvIII
were resistant against reversible EGFR-TKIs, but remained
sensitive to irreversible EGFR inhibitors [28]. We found the best
correlation with TS12 and exon 18. At the extremities of the
EGFR gene several exonic probesets did not show a significant
association with outcome. Dziadziuszko and colleagues reported
that high EGFR mRNA expression analyzed by quantitative RT-
PCR was associated with increased response and prolonged PFS in
patients treated with gefitinib [29]. In a Chinese study of 79
unselected patients treated with erlotinib no significant correlation
between EGFR mRNA expression, EGFR mutations, KRAS
mutations and clinical endpoints was found [30].
Several trials demonstrated that clinical benefit with EGFR-
TKIs was not restricted to patients with activating EGFR
mutations [13,16,31]. On the other hand, the IPASS trial
demonstrated that patients with EGFR wild-type treated with
gefitinib had a significantly shorter PFS compared with patients in
the chemotherapy arm (hazard ratio (HR): 2.85; 95% CI: 2.05–
3.98; pv0:001) [8]. In the present study, we were able to identify
3 patients with EGFR wild-type and high exon 18-EGFR
expression levels (2 measured in biopsies and blood, and 1
measured in blood only) who had significant TS12 after treatment
with BE. We believe that these results are of interest, because the
incidence of activating EGFR mutations in Caucasian patients is
10–15% and our test may identify additional patients who could
Table 2. Cont.






74 61 M IV never smoker 1 no no 66
75 61 M IV never smoker 0 no no NA
77 54 M IV smoker 1 no no 16
78 63 F IV smoker 1 Del L747-G749 NA 26
79 32 F IIIB never smoker 1 Del E746-A750 no 100
80 44 F IV smoker 0 NA NA no NA
81 55 M IV smoker 0 no no NA
82 58 M IV smoker 1 no no 0
83 53 F IV smoker 0 no G12D NA
84 55 F IV never smoker 1 NA NA 0
85 48 F IV smoker 1 no no 0
86 56 F IV smoker 0 NA NA NA
87 74 M IV smoker 1 no no 215
88 78 M IV never smoker 0 no no 23
89 69 F IV never smoker 1 Del R748-S752 no 62
90 69 F IV smoker 1 no no 0
91 68 M IV smoker 0 no no NA
92 64 F IV never smoker 1 Del E746-A750 no 39
93 56 F IV never smoker 1 E709A and G719S no 12
94 49 F IV smoker 1 no G12V 16
95 64 M IV smoker 1 NA NA 1
96 77 M IV smoker 0 no no NA
98 64 F IV never smoker 1 no no 18
99 48 M IV smoker 1 no no 26
101 66 M IV smoker 0 no no 21
102 59 F IV smoker 1 no no 28
103 72 F IV never smoker 1 Del E746-A750 no 76
Abbreviations: DST W12: disease stabilization week 12, 0 = failure, 1 = success; EGFR mut (18–21): EGFR mutation in exons 18–21; KRAS mut (12): KRAS mutation in exon
12; W12: week 12.
doi:10.1371/journal.pone.0072966.t002
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fare better with first-line EGFR-TKIs compared with chemother-
apy. This hypothesis needs prospective validation.
Interestingly, patients with rarer EGFR-mutations (e.g. del
L747-S751 and del R748-S752) for which the response to
EGFR-TKIs has yet to be explored were also found to have
higher exon-level EGFR expression levels which was correlated
with TS12. Two probesets located on exon 18 showed the
strongest association with tumor shrinkage. In an Italian single
institution study, rare EGFR-mutations (exon 18 and 20 and
uncommon mutations in exons 19 and 21 and/or complex
mutations) were found in 2.6% of patients. They reported PR to
erlotinib in a patient with a E709A+G719C double mutation and
a response to erlotinib in a patient with a G719S mutation [32].
Other groups reported sensitivity to EGFR-TKI for the
E709A+G719C double mutation and for the G719S mutation in
exon 18 [33–35].
Interestingly, we observed tumor shrinkage in one patient with a
KRAS mutation. This patient had a high EGFR exon expression.
Patients with KRAS mutations represent approximately 25% of
NSCLC patients and have been described as highly resistant to
EGFR-TKI treatment with RR close to 0% and worse outcome
for mutated patients treated with EGFR-TKIs in some trials
[36,37]. The biomarker analysis of the SATURN trial showed no
detrimental effect on PFS with erlotinib in patients with KRAS
mutant tumors [17]. Thus, high exon EGFR expression levels may
be able to identify patients with KRAS mutations who derive
benefit from first-line BE.
Other potential molecular markers beyond EGFR-mutations
have been investigated for their predictive role for treatment with
TKIs or TKIs in combination with VEGFR inhibitors. EGFR
protein expression detected by immunohistochemistry (IHC) is
present in 60–90% of NSCLC patients [13,38] and therefore
unlikely to be of use for clinical selection for TKI therapy.
Although subgroup analyses of placebo controlled phase III studies
in pre-treated patients showed some predictive value of EGFR
protein expression [13,39], these results were not confirmed either
in the first line or maintenance setting [17,40]. Similarly, high
EGFR copy number, which occurs in 30–50% of patients with
NSCLC, and gene amplification, which occurs in about 10% [41],
have recently been shown to be JoverruledJ by EGFR mutations
Figure 1. Chromosomal location of the Affymetrix exon array probesets within EGFR, KRAS and VEGFA. The red ticks show the exonic
probesets, the gray ticks display the non-exonic probesets (intronic, intergenic and unreliable). In EGFR, KRAS and VEGFA, a total of 51 of 451, 13 of
262 and 25 of 26 exonic probesets were measured respectively. All other probesets were situated outside of exons, i.e. intronic, intergenic or were
unreliable.
doi:10.1371/journal.pone.0072966.g001
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with respect to their predictive value for the response to EGFR-
TKIs [40]. Determination of EGFR mRNA expression by
quantitative PCR was correlated to EGFR FISH and IHC and
was shown to be a predictive biomarker for gefitinib [29]. Neither
EGFR protein expression nor EGFR FISH testing are currently
used in clinical practice and better molecular markers are
therefore urgently needed.
The EGFR gene gives rise to multiple RNA transcripts through
alternative splicing and the use of alternate polyadenylation signals
[42]. The EGFR gene spans nearly 200 kb and the full-length
170 kDa EGFR is encoded by 28 exons. Several alternative
splicing variants have been described [43]. The most commonly
used method to detect EGFR-mutations is direct sequencing of the
PCR-amplified exon sequences. The copy number of mutant
allele, imbalanced PCR amplification and the relative amount of
contaminating wild-type allele of non-tumor cells can influence the
sensitivity of mutant detection by direct sequencing [44]. Owing to
concern regarding the sensitivity of the direct-sequencing method,
a variety of other methods have been investigated to increase the
sensitivity of the mutation assay. Here we investigated for the first
time exon expression analysis. The array used enables gene
expression analysis as well as detection of different isoforms of a
gene. In this study we retrospectively identified a correlation
between exon intensity levels within EGFR and patient outcome.
The mechanism through which EGFR exon 18 expression
determines an increased sensitivity to bevacizumab-erlotinib is
unknown, although different hypotheses can be proposed. Exon
array is still very recent with high potential technology. It brakes
with the common idea that gene expression is stable over the span
of a whole gene. Therefore, it is not surprising that we obtained a
stronger statistical correlation EGFR expression near the region
coding for the functional transmembrane part of EGFR. If the
predictive value of this assay could be confirmed in a prospective
trial, exon-level gene expression might identify patients deriving
benefit from EGFR- and VEGFR-targeted therapies beyond the
patients selected by conventional gene sequencing.
There are certain limitations within the current study. It is a
single arm design and has a relatively low number of patients from
which tumor biopsies were available for analysis. In the first half of
the SAKK 19/05 trial a treatment-naive biopsy was not required
for study inclusion. In this period practically no biopsies were
collected. After an amendment (October 2006) the biopsy became
mandatory for study inclusion as a treatment-naive biopsy can be
taken in almost every patient including advanced-stage NSCLC
Figure 2. Association between EGFR, KRAS and VEGFA exon-level expression and response to BE. Row A depicts the association
between the tumor shrinkage at week 12 and the exon-level composite score (PCA axis 1) for EGFR, KRAS and VEGFA (left, center and right
respectively). The PCA scores are defined as the coordinates of the patients in a new space defined by linear combination of the original probeset
intensity values using principal component analysis. The patients with EGFR mutations are marked in red, those with non-available mutational status
are shown as empty circles. The row B shows the significance of the correlation (2log(p-value)) between each exon probeset and the tumor
shrinkage at week 12. The position of the exons is shown in blue.
doi:10.1371/journal.pone.0072966.g002
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patients [23]. Exon array analyses were done with mixed cell
tumor biopsies without any tumor-cell enriching technique like
laser-capture microdissection. This is likely to lead to a certain
dilution of the true tumor signal. Tumor-cell enriching techniques
might further optimize the efficiency of biomarkers derived from
exon array analyses. The validity of EGFR exon expression
analysis as a biomarker of response to BE will need to be
confirmed both using RT-PCR analysis targeting EGFR exon 18.
The full accomplishment of the validation of the novel biomarker
eventually requires further investigation using an independent
prospective randomized trial.
In conclusion, with the aid of a novel gene expression array
technology with exonic coverage, we were able to identify exon 18-
EGFR expression as a potential predictive biomarker for erlotinib
and bevacizumab in patients with advanced, untreated NSCLC.
Materials and Methods
SAKK 19/05
The SAKK 19/05 trial (ClinicalTrials.gov: NCT00354549)
enrolled 103 patients with advanced non-squamous NSCLC, 101
patients were evaluable for further analysis [21]. Eligibility criteria
included agew18 years, adequate bone marrow function, normal
kidney and liver function and measurable disease. Patients with
immediate need of chemotherapy, with large centrally located
tumors, pre-existing tumor cavitations and brain metastases were
excluded. Extra pre-treatment bronchoscopic biopsies for transla-
tional studies were taken in 49 patients, from which 42 were of
sufficient quality for subsequent exon array analysis. For the
present substudy, pretreatment blood samples were available from
95 patients, and samples from 75 patients had sufficient quality for
exon arrays. Overall, 76 patients with either tumor or blood
samples or both, were included in the current substudy. Written
informed consent for translational research was obtained from all
patients. The clinical trial as well as the current substudy were
approved by the IRB of St. Gallen (EKSG 06/012).
Trial design
SAKK 19/05 was a multicenter, prospective, open-label, single-
arm, phase II trial in previously untreated patients. From January
2006 to April 2009, 103 patients from 14 Swiss institutions were
enrolled and received BE until disease progression or unacceptable
toxicity. At the time of progression, patients received chemotherapy
with 4–6 cycles of cisplatin and gemcitabine. The primary endpoint
was disease stabilization rate (DSR) defined as the proportion of
patients with complete response (CR), partial remission (PR) or
stable disease (SD) after 12 weeks of BE treatment. Secondary
endpoints included TTP under BE, as well as under CT, overall
survival (OS), tumor shrinkage at 12 weeks and 6 months. The
clinical outcomes of this trial have been reported earlier [21].
Pathology analysis
The formalin-fixed and paraffin embedded specimens were
reviewed and classified according to World Health Organisation
(WHO) criteria. Mutational analyses of EGFR (exon 18–21) and
KRAS (exon 12) were carried out from unstained tissue sections
(3 mm) or Papanicolaou-stained cytological specimens using direct
sequencing as previously described [45,46]. Tumor cell enrich-
ment was achieved either by macrodissection or laser-capture
microdissection and DNA sequence analysis.
Exon-level gene expression analysis
Total RNA from whole bronchoscopic biopsy samples were
extracted and provided sufficient quality for microarray hybrid-
ization in 42 of 49 samples. Circulating RNA from peripheral
blood samples was extracted and provided sufficient quality for
microarray hybridization in all 75 samples. mRNA was hybridized
on Affymetrix Human Exon 1.0ST arrays (Affymetrix, Santa-
Clara, CA, USA) following standard recommendations from the
manufacturer (detailed procedure available in Text S1). Raw data
have been deposited in NCBIs Gene Expression Omnibus (GEO),
and are accessible through GEO Series accession number
GSE37138. The exon and gene level probesets were pre-
processed, quality checked and normalized using the RMA
procedure [47]. The tissue and blood datasets were analyzed
Figure 3. Exon 18-EGFR expression is associated with tumor shrinkage. The left panel depicts the correlation between the expression
intensity of the exon 18-EGFR (probeset 3002770) and the tumor shrinkage at week 12. The vertical line shows the median expression intensity of
EGFR probeset 3002770. Patients with EGFR mutations are shown as red plain dots and labelled accrodingly. Patients with non-available mutational
status are displayed as empty circles. The central panel represents the receiver operating characteristic (ROC) curve showing the sensitivity/specificity
of a test based on the expression level of EGFR probeset 3002770 to classify responders (tumor shrinkage at week 12w0/20/30%) vs. non-responders
(tumor shrinkage at week 12ƒ0/20/30%). The plain dots depict the true positive and false positive rates obtained by fixing the cutoff value to the
median expression level of EGFR 3002770. The waterfall plot (right panel) displays the change in tumor size at week 12 ordered from left to right. The
colors are defined by the expression intensity of EGFR 3002770 dichotomized by the median of the expression evel (blue: low expression intensities;
red: high expression intensities).
doi:10.1371/journal.pone.0072966.g003
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independently without pooling the data. The tissue dataset was
used for biomarker discovery whereas the blood dataset was used
for internal validation.
Statistical considerations
The initial sample size calculation was based on the primary
endpoint of the clinical study (DSR at week 12 (DSR12) under BE
treatment). The 101 evaluable patients accrued guaranteed a high
precision in the estimation of DSR12. In a targeted gene
approach, 3 genes were specifically investigated: EGFR
(ENSG00000146648), KRAS (ENSG00000133703) and VEGFA
(ENSG00000112715). EGFR included 51, KRAS 13, and
VEGFA 25 exonic probesets (Figure 1). The endpoints considered
in this biomarker study included tumor shrinkage after 12 weeks
(TS12) of BE treatment, TTP under BE and OS. OS was
measured from registration until death of any cause. The result of
previous tumor EGFR sequencing was used for substudy analysis.
The univariate association between the exon-level intensities and
time-to-event endpoints was assessed by Cox proportional hazards
regression. The correlation between exon-level intensities and
tumor shrinkage was measured using the Spearman’s correlation
coefficient r and tested for significant difference from 0.
Bonferroni corrections were used to account for multiple testing.
Principal component analysis (PCA) was used to summarize the
information included in several exon-level probesets into compos-
ite scores (scores on the first principal components). Receiver
Operating Characteristic (ROC) curves were used to estimate the
sensitivity, specificity and accuracy of exon expression based
predictors. In order to assess the stability of our findings, a cross-
validation strategy was used. The accuracy of the classification
model was evaluated using bootstrapping. All analyses were done
using the R statistical software (version 2.13.0; packages xmapcore,
ade4, ROCR, Daim and survival) [48].
Supporting Information
Figure S1 Association between EGFR exon 18 expres-
sion and tumor shrinkage at week 12 — sub-analysis.
Only EGFR wild type patients were included in this analysis. The
scatter plot depicts the correlation between the expression of
EGFR exon 18 (probeset 3002770) and the tumor shrinkage at
week 12. The vertical line shows the median expression intensity of
EGFR exon 18.
(TIF)
Figure S2 Stability of the prediction ability of EGFR
biomarkers using cross-validation strategies. The left
panel depicts the ability of the EGFR biomarker most significantly
associated with TS12 (#/.20%) using the original dataset
(probeset 3002770) to classify BE responders. The best cut-off
value, together with the associated false positive rate (FPR), true
positive rate (TPR) and area under ROC curve (AUC) are given.
The right panel depicts the averaged ROC curve obtained after
.632 bootstrap cross-validation procedure. The boxplots show the
distribution of the FPR throughout the re-sampled datasets.
(TIF)
Table S1 Summary of all patients included in the SAKK
19/05 trial. DST W12: disease stabilization week 12, 0 = failure,
1 = success.
(PDF)
Text S1 Additional material and methods information.
The first paragraph provides an extended description of the exon-
level gene expression analysis. The second paragraph gives details
about the assessment of the stability of the obtained results.
(PDF)
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